Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dual specificity protein phosphatase 23 (DUSP23) is a small (≈150–amino acid) enzyme that catalyzes the dephosphorylation of both phosphotyrosine and phosphoserine/threonine residues on substrate proteins. DUSP23 localizes predominantly to the cytoplasm and centrosome, where it regulates G1/S cell cycle progression, cell proliferation, and cell–cell adhesion by dephosphorylating β-catenin at Tyr142, thereby strengthening α–/β–catenin interactions and stabilizing E-cadherin–mediated adherens junctions. It is structurally classified as the smallest catalytically active dual specificity phosphatase and plays roles in signaling pathways relevant to tumorigenesis, angiogenesis, and epithelial tissue homeostasis.
Drugs targeting DUSP23 would function as phosphatase modulators, altering dephosphorylation of key signaling proteins such as ERK1, JNK, p38, and β-catenin
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dual specificity protein phosphatase 23 (DUSP23).